Tiotropium Respimat is an inhaled corticosteroid drug patients administer once daily through Boehringer Ingelheim’s Respimat inhaler.
The FDA first approved the drug in 2015 for asthma patients age 12 and older. Now, the drug can also be used to treat children ages six and up.
More articles on supply chain:
4 thoughts from Trump’s CMS pick on reducing federal drug spending
Prime Therapeutics reports 2.5% increase in drug spending for 2016
FDA approves Valeant’s psoriasis drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
